farletuzumab ecteribulin (MORAb-202) / Eisai - LARVOL DELTA

Baseline tumor genomic features associated with efficacy outcomes of farletuzumab ecteribulin (FZEC) antibody-drug conjugate (ADC) therapy (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Clinical • Oncology

Open label, multicenter, phase II study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib (LEN) in platinum-resistant ovarian cancer (PROC) (ESMO-Gynae 2026) - P1/2 | "Up to 3 prior lines of systemic therapy are allowed; up to 4 prior lines of therapy are permitted for pts who received prior mirvetuximab soravtansine. Previous bevacizumab maintenance therapy will not count as an independent line of therapy...Adverse events will be monitored and graded according to CTCAE v5.0; interstitial lung disease events will be carefully monitored/managed. This multinational study is actively recruiting; as of March 19, 2026, 6 pts have been enrolled and treated."

ADC • Clinical • Combination therapy • P2 data • Platinum resistant • Fallopian Tube Cancer • Gynecologic Cancers • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CTSB • FOLR1

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Bristol-Myers Squibb | N=100 ➔ 50

Enrollment change • Metastases • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Comprehensive profiling of antibody-drug conjugate target expression in epithelial ovarian cancer with pre- and post-ADC longitudinal assessment. (ASCO 2026) - "In ADC-exposed paired pre-/post-ADC specimens, expression of the cognate ADC target generally decreased after exposure, including reduced FOLR1 after MIRV/MORAb-202, reduced HER2 after T-DXd, and reduced CDH6 after R-DXd. TROP2 and FOLR1 are broadly and consistently expressed across timepoints. Non-HGSC exhibits distinct histology-specific patterns, with particularly high HER2 expression in mucinous tumors. ADC treatment resulted in a reduced expression profile of its cognate target protein, which may contribute to the development of ADC resistance; however, further investigation is required to elucidate additional underlying mechanisms."

ADC • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD276 • CDH6 • CLDN6 • FOLR1 • HER-2 • VTCN1

ACSL4 mediated ferroptosis and its potential role in enhancing the efficacy of antibody-drug conjugates (AACR 2026) - "This study investigated whether ADC conjugation can fundamentally reprogram payload pharmacology and clarified the downstream consequences for antitumor efficacy and immune activation beyond conventional delivery advantages.Experimental Design: Using MORAb-202, an ADC consisting of the clinically approved eribulin linked to a folate receptor alpha (FRα)-targeting antibody, we performed intratumoral pharmacokinetic/pharmacodynamic (PK/PD) and pharmacometabolomic analyses in xenograft models with varying FRα expression...Therapeutic efficacy was tested as monotherapy and in combination with pembrolizumab in a human peripheral blood mononuclear cells co-implantation model. ADC-conjugated eribulin achieved >20-fold higher intratumoral retention of eribulin compared to the free eribulin in AUC value... ADC conjugation reprograms payload's pharmacodynamics, inducing ferroptosis and ICD unattainable with free payload, even at clinically equivalent doses. This highlights..."

ADC • Clinical • IO biomarker • Oncology • ACSL4 • FOLR1 • GPX4 • HMGB1

Novel ALDC and ADC with TMEAlinker and eribulin payload demonstrate excellent safety and efficacy in preclinical evaluation (AACR 2026) - "TMEAlinkers (TME-activated linkers) are legumain-activated linkers with clinical proof-of-concept (POC) from the phase 3 study of legubicin (an albumin drug conjugate, ALDC)...In cynomolgus monkeys, IMD2128 was well tolerated with a highest nonseverely toxic dose (HNSTD) over 16 mg/kg, showing a superior safety profile compared to VC linker-eribulin based ADCs (e.g., MORAb-202, HNSTD = 1.95 mg/kg). Pharmacokinetic studies in monkeys revealed a Cmax of 291.07 µmol/mL for IMD2128 ADC versus a Cmax of 0.0000823 µmol/mL for free eribulin (Cmax ratio ≈ 3.54 × 10⁶ : 1), confirming strong linker stability in circulation. Together, these findings highlight the versatility of the TMEAlinker platform for developing both ALDCs and ADCs with eribulin payloads, demonstrating excellent safety and efficacy in preclinical evaluations."

ADC • Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • LGMN • MET

Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. (PubMed, JTO Clin Res Rep) - P1 | "FZEC demonstrated modest antitumor activity, and observed AEs were generally manageable in patients with heavily pretreated NSCLC. NCT03386942."

Journal • P1 data • Interstitial Lung Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • FOLR1

Antitumor effect of farletuzumab ecteribulin in molecular subtypes of endometrial cancer patient-derived xenograft models (AACR 2025) - "FZEC demonstrated robust antitumor effect against the FRα high EC-PDX models. Importantly, significant antitumor effects were observed, even in FRα-low or negative models. Intratumoral eribulin accumulation exhibited a stronger correlation with efficacy than with FRα expression alone."

Preclinical • Endometrial Cancer • Oncology • Solid Tumor • FOLR1

Open label, multicenter, phase 2 study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib in platinum-resistant ovarian cancer (PROC) (SGO 2026) - No abstract available

ADC • Clinical • Combination therapy • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer (ESGO 2026) - P1/2 | "As such, we are conducting Study 201 Dose Optimization part B (NCT04300556) in patients with platinum-resistant ovarian cancer (PROC).Methodology Eligible patients (≥18years) must have a confirmed diagnosis of platinum-resistant, high-grade serous ovarian cancer/primary peritoneal cancer/fallopian tube cancer, an ECOG-PS of 0/1, and ≤3 prior lines of systemic therapy (4 prior lines permitted for patients with prior mirvetuximab soravtansine). Previous bevacizumab maintenance therapy will not count as an independent therapy...Adverse events will be monitored and graded according to CTCAE v5.0; interstitial lung disease events will be carefully monitored/managed. This multinational study is actively recruiting.Results n/aConclusion n/a"

Clinical • Combination therapy • P2 data • Platinum resistant • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CTSB • FOLR1

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. (PubMed, Int J Gynaecol Obstet) - P1 | "FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC."

Journal • P1 data • Platinum resistant • Interstitial Lung Disease • Oncology • Ovarian Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • FOLR1

Open label, multicenter, phase 2 study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib in platinum-resistant ovarian cancer (PROC) (AACR-NCI-EORTC 2025) - P1/2 | "Up to 3 prior lines of systemic therapy are allowed; up to 4 prior lines of therapy are permitted for patients who received prior mirvetuximab soravtansine. Previous bevacizumab maintenance therapy is permitted and is not counted as an independent line of therapy...Adverse events will be monitored and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; interstitial lung disease events will be carefully monitored and managed. This multinational study is actively recruiting."

Clinical • Combination therapy • Late-breaking abstract • P2 data • Platinum resistant • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CTSB • FOLR1

CA116-001: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P2 | N=106 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ Sep 2025

Platinum resistant • Trial completion • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • FOLR1

MORAb-202-G000-201: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (clinicaltrials.gov) - P1/2 | N=182 | Recruiting | Sponsor: Eisai Inc. | Trial completion date: Dec 2024 ➔ Aug 2030 | Trial primary completion date: Dec 2024 ➔ Aug 2030

Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • ER • HER-2 • PGR • ROS1

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) (clinicaltrials.gov) - P2 | N=31 | Terminated | Sponsor: Bristol-Myers Squibb | N=50 ➔ 31

Enrollment change • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys. (PubMed, J Pharm Biomed Anal) - "Following intravenous administration, the PK profiles of Tab and ADC were similar, while minimal levels of eribulin. No ADA against MORAb-202 was detected in postdose samples."

Journal • PK/PD data • Oncology • CTSB • FOLR1

Antitumor Effect of Farletuzumab ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. (PubMed, Mol Cancer Ther) - "Notably, intratumoral eribulin accumulation exhibited a stronger correlation with efficacy than with FRα expression alone. These findings support further clinical development of FZEC for EC treatment and highlight the complexity of the mechanisms of action of ADCs."

Journal • Preclinical • Endometrial Cancer • Oncology • Solid Tumor • FOLR1

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models. (PubMed, Clin Transl Med) - No abstract available

Journal • Preclinical • Gynecologic Cancers • Oncology • FOLR1 • MSLN

The Efficacy And Safety Of Folate Receptor a-Targeted Antibody-Drug Conjugate Therapy In Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers: A Systematic Review And Meta-Analysis (ESGO 2025) - "The protocol was registered with PROSPERO (CRD42023491151).Results Ten studies with a total of 940 patients (859 treated with mirvetuximab soravtansine-gynx (MIRV), 45 with farletuzumab ecteribulin (MORAb-202), and 36 with luveltamab tazevibulin (STRO-002)) were included in this meta-analysis. The incidence of grade ≥3 adverse events was 27% (95% CI: 0.19–0.36).Conclusion FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second-line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort."

Retrospective data • Review • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

Preclinical evaluation of farletuzumab ecteribulin (FZEC) and MORAb-109, antibody-drug conjugates (ADCs) targeting folate receptor alpha and mesothelin, in high-risk gynaecological cancers. (LCC 2025) - " Eribulin demonstrated activity in 11 out of 15 gynaecological cancer models, outperforming the standard anti-microtubule agent, paclitaxel, despite 80% of models being resistant to cisplatin. The 15 aggressive gynaecological cancer PDX models showed remarkable responses to FZEC and MORAb-109 when FRA and/or MSLN expression was positive and ABCB1 expression was low. Given the limited treatment options for advanced gynaecological cancer, our findings underscore the urgent need to include these cancers in eribulin ADC trials early in the disease course."

Preclinical • Carcinosarcoma • Clear Cell Carcinoma • Endometrial Serous Adenocarcinoma • Gynecologic Cancers • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Uterine Cancer • ABCB1 • FOLR1 • MSLN

Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. (PubMed, J Clin Pharmacol) - "Dosing simulations showed that BSA-based dosing (33 mg/m2) yielded similar tumor responses to BW-based dosing (0.9 mg/kg) and decreased ILD rates. This study showed that BW-based dosing resulted in higher risks of ILD events for patients with a high BW versus low BW, whereas BSA-based dosing is predicted to reduce this risk while maintaining clinical efficacy."

Journal • PK/PD data • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor

The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis. (PubMed, Cancer Med) - "FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second-line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort."

Clinical • Journal • Retrospective data • Review • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

CA116-001: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Enrollment closed • Fallopian Tube Cancer • Oncology • Ovarian Cancer • FOLR1

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) (clinicaltrials.gov) - P2 | N=50 | Terminated | Sponsor: Bristol-Myers Squibb | Trial completion date: Feb 2026 ➔ Aug 2024 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2024 ➔ Aug 2024; Business objectives have changed

Metastases • Trial completion date • Trial primary completion date • Trial termination • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MORAb-202-G000-201: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (clinicaltrials.gov) - P1/2 | N=142 | Recruiting | Sponsor: Eisai Inc. | Trial completion date: Mar 2025 ➔ Oct 2024 | Trial primary completion date: Mar 2025 ➔ Oct 2024

Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • ER • HER-2 • PGR • ROS1